CN112672748A - Rig-i激动剂以及使用其的治疗 - Google Patents

Rig-i激动剂以及使用其的治疗 Download PDF

Info

Publication number
CN112672748A
CN112672748A CN201980055031.8A CN201980055031A CN112672748A CN 112672748 A CN112672748 A CN 112672748A CN 201980055031 A CN201980055031 A CN 201980055031A CN 112672748 A CN112672748 A CN 112672748A
Authority
CN
China
Prior art keywords
cancer
nucleic acid
tumor
rig
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201980055031.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·岩崎
A·M·派尔
X·蒋
O·费多罗瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of CN112672748A publication Critical patent/CN112672748A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980055031.8A 2018-06-20 2019-06-20 Rig-i激动剂以及使用其的治疗 Withdrawn CN112672748A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862687606P 2018-06-20 2018-06-20
US62/687,606 2018-06-20
US201862743369P 2018-10-09 2018-10-09
US62/743,369 2018-10-09
US201962815870P 2019-03-08 2019-03-08
US62/815,870 2019-03-08
PCT/US2019/038323 WO2019246450A1 (en) 2018-06-20 2019-06-20 Rig-i agonists and treatments using same

Publications (1)

Publication Number Publication Date
CN112672748A true CN112672748A (zh) 2021-04-16

Family

ID=68982664

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980055031.8A Withdrawn CN112672748A (zh) 2018-06-20 2019-06-20 Rig-i激动剂以及使用其的治疗

Country Status (6)

Country Link
US (3) US12472198B2 (enExample)
EP (1) EP3810151B1 (enExample)
JP (1) JP2021529173A (enExample)
CN (1) CN112672748A (enExample)
CA (1) CA3110102A1 (enExample)
WO (1) WO2019246450A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114814231A (zh) * 2022-03-08 2022-07-29 上海交通大学医学院附属瑞金医院 维甲酸诱导基因i在癌症治疗中的应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
PL3429618T3 (pl) 2016-03-16 2024-07-01 Amal Therapeutics Sa Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie
HUE067838T2 (hu) 2016-09-21 2024-11-28 Amal Therapeutics Sa Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére
JP7366057B2 (ja) 2018-04-19 2023-10-20 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト
EP3863675A4 (en) * 2018-10-09 2023-09-06 Yale University RIG-I AGONISTS AND METHODS OF USE THEREOF
EP4054560A4 (en) * 2019-11-04 2023-11-29 Yale University RIG-I INNATE IMMUNE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF
JP2023545178A (ja) * 2020-10-14 2023-10-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｔｉｎｇアゴニストと、細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む複合体との組合せ
US11786545B2 (en) * 2020-12-09 2023-10-17 Yale University Compositions and methods for treating SARS-CoV-2 infection
AU2022302143A1 (en) 2021-07-02 2024-01-18 Yale University Compositions and methods for treating cancers
EP4395832A1 (en) 2021-08-31 2024-07-10 Yale University Compositions and methods for treating cancers
US20230303719A1 (en) 2022-03-03 2023-09-28 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
WO2025040743A1 (en) 2023-08-22 2025-02-27 Univerza V Ljubljani Conjugated tlr7 and rig-i agonists
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228450A (zh) * 2013-05-18 2016-01-06 艾杜罗生物科技公司 用于活化“干扰素基因刺激因子”-依赖性信号传导的组合物和方法
US20160046943A1 (en) * 2013-03-13 2016-02-18 Yale University Interferon Production Using Short RNA Duplexes
WO2018033254A2 (en) * 2016-08-19 2018-02-22 Curevac Ag Rna for cancer therapy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
ES2192672T3 (es) 1996-11-18 2003-10-16 Takeshi Imanishi Nuevos analogos de nucleotidos.
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6143877A (en) 1997-04-30 2000-11-07 Epoch Pharmaceuticals, Inc. Oligonucleotides including pyrazolo[3,4-D]pyrimidine bases, bound in double stranded nucleic acids
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
US6127121A (en) 1998-04-03 2000-10-03 Epoch Pharmaceuticals, Inc. Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
DE60029314T2 (de) 1999-03-24 2007-07-12 Exiqon A/S Verbesserte Synthese für -2.2.1. I Bicyclo-Nukleoside
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6287778B1 (en) 1999-10-19 2001-09-11 Affymetrix, Inc. Allele detection using primer extension with sequence-coded identity tags
US6660845B1 (en) 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
US20090247613A1 (en) 2002-02-20 2009-10-01 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
WO2004092383A2 (en) 2003-04-15 2004-10-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) VIRUS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2538169A1 (en) 2003-09-09 2005-03-17 Albert Einstein College Of Medicine Of Yeshiva University Transition state analog inhibitors of ricin a-chain
US20080293053A1 (en) 2006-12-28 2008-11-27 The Regents Of The University Of Michigan shRNA Materials and Methods of Using Same for Inhibition of DKK-1
US20090123501A1 (en) 2007-05-17 2009-05-14 Baylor College Of Medicine Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines
EP2257313A2 (en) 2008-02-21 2010-12-08 University of Kentucky Research Foundation Ultra-small rnas as toll-like receptor-3 antagonists
CA2721183C (en) 2008-04-11 2019-07-16 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
US20110251258A1 (en) 2008-07-24 2011-10-13 Rxi Pharmaceuticals Corporation Rnai constructs and uses thereof
JP2012505657A (ja) 2008-10-15 2012-03-08 ソマジェニックス インク． 遺伝子発現の阻害のためのショートヘアピンｒｎａ
WO2010111891A1 (zh) 2009-04-03 2010-10-07 北京大学 修饰的寡聚核酸分子及其制备方法和应用
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
JP2015502365A (ja) 2011-12-12 2015-01-22 オンコイミューニン，インコーポレイティド オリゴヌクレオチドのイン−ビボ送達
US10392444B2 (en) * 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
KR102129195B1 (ko) 2016-02-15 2020-07-01 에프케이디 테라피즈 리미티드, 향상된 인터페론 치료
WO2017173427A1 (en) 2016-04-01 2017-10-05 Vycellix Inc Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
US11382966B2 (en) * 2017-03-24 2022-07-12 Rigontec Gmbh Method for designing RIG-I ligands
US10710272B2 (en) 2017-12-14 2020-07-14 United Technologies Corporation Hybrid material airflow impression molds
CA3086040A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
US10736957B2 (en) 2017-12-19 2020-08-11 President And Fellows Of Harvard College Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences
US12539308B2 (en) 2018-01-08 2026-02-03 The Trustees Of The University Of Pennsylvania Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
WO2019143297A1 (en) 2018-01-17 2019-07-25 Nanyang Technological University Immunomodulatory small hairpin rna molecules
JP7366057B2 (ja) 2018-04-19 2023-10-20 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160046943A1 (en) * 2013-03-13 2016-02-18 Yale University Interferon Production Using Short RNA Duplexes
CN105228450A (zh) * 2013-05-18 2016-01-06 艾杜罗生物科技公司 用于活化“干扰素基因刺激因子”-依赖性信号传导的组合物和方法
WO2018033254A2 (en) * 2016-08-19 2018-02-22 Curevac Ag Rna for cancer therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114814231A (zh) * 2022-03-08 2022-07-29 上海交通大学医学院附属瑞金医院 维甲酸诱导基因i在癌症治疗中的应用

Also Published As

Publication number Publication date
WO2019246450A1 (en) 2019-12-26
JP2021529173A (ja) 2021-10-28
CA3110102A1 (en) 2019-12-26
US20200061097A1 (en) 2020-02-27
EP3810151A4 (en) 2022-03-23
US12472198B2 (en) 2025-11-18
EP3810151B1 (en) 2025-08-06
US20230201242A1 (en) 2023-06-29
EP3810151A1 (en) 2021-04-28
US20210260093A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
EP3810151B1 (en) Rig-i agonists and treatments using same
US20240368607A1 (en) Synthetic rig-i-like receptor agonists
US20210054380A1 (en) Interferon Production Using Short RNA Duplexes
EP3704269B1 (en) Oligonucleotide constructs and uses thereof
JP4623426B2 (ja) オリゴ核酸担持複合体、当該複合体を含有する医薬組成物
US20250255898A1 (en) Compositions and methods for tumor immunotherapy
WO2015108048A1 (ja) 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
HK40050932A (en) Rig-i agonists and treatments using same
CN113286601A (zh) Foxp3表达的调节剂
US20230159923A1 (en) RIG-I Agonists and Methods of Using Same
EP4719437A1 (en) Connector modified synthetic rig-i agonists and methods of using the same
CN120456911A (zh) 用于抑制补体组分C3(C3)表达的RNAi剂、其药物组合物及使用方法
TW202342745A (zh) 新型共軛核酸分子及其用途
HK40059024A (en) Modulators of foxp3 expression

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40050932

Country of ref document: HK

WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20210416